Shixiu Wu

Hangzhou Cancer Hospital is a specialized medical and research institution in China that has gained international recognition for its pioneering work in advanced cancer therapies, particularly under the leadership of President Shixiu Wu. The institution functions as a major clinical hub for the development and testing of chimeric antigen receptor T-cell (CAR-T) therapies for solid tumors, an area where traditional cell therapies have historically struggled. Their research portfolio includes innovative trials targeting CEA, Mesothelin, and GPC3 across various gastrointestinal and thoracic malignancies. Beyond cell therapy, the hospital integrates traditional radiotherapy with modern immunotherapy and gene-edited treatments to improve patient outcomes in refractory cases.